Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer

Future Oncology

Volumn 7, Issue 3, 2011, Pages 467-474

  Sinicrope, Frank A ^a   Yang, Zhineng Jayson ^a  

^a MAYO CLINIC CANCER CENTER   (United States)

Author keywords

adjuvant therapy; colorectal cancer; DNA mismatch repair; Lynch syndrome; microsatellite instability

Indexed keywords

CAPECITABINE; FLUOROURACIL; IRINOTECAN; MISMATCH REPAIR PROTEIN PMS2; OXALIPLATIN; PROTEIN MLH1; PROTEIN MSH2;

CANCER STAGING; CANCER THERAPY; CARCINOGENESIS; CLINICAL DECISION MAKING; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG EFFICACY; GENE SILENCING; GENETIC ASSOCIATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; MISMATCH REPAIR; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE;

COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; HUMANS; MICROSATELLITE INSTABILITY; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953126786     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.5     Document Type: Review

References (67)

1. Grady WM, Carethers JM: Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135(4), 1079-1099 (2008).
2. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363(6429), 558-561 (1993). (Pubitemid 23186645)
3. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl Acad. Sci. USA 95(12), 6870-6875 (1998). (Pubitemid 28278073)
4. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP: CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96(15), 8681-8686 (1999). (Pubitemid 29354851)
5. Nagasaka T, Rhees J, Kloor M, et al. Somatic hypermethylation of MSH2 is a frequent event in Lynch syndrome colorectal cancers. Cancer Res. 70(8), 3098-3108 (2010).
6. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 260(5109), 816-819 (1993). (Pubitemid 23167612)
7. Jass JR, Do KA, Simms LA, et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut 42(5), 673-679 (1998). (Pubitemid 28261055)
8. Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol. Biomarkers Prev. 10(9), 917-923 (2001). (Pubitemid 32844897)
9. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR: Histopathological identification of colon cancer with microsatellite instability. Am. J. Pathol. 158(2-, 527-535 (2001). (Pubitemid 32158613)
10. Greenson JK, Bonner JD, Ben-Yzhak O, et al. Phenotype of microsatellite unstable colorectal carcinomas: well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am. J. Surg. Pathol. 27(5), 563-570 (2003). (Pubitemid 36514468)
11. Poynter JN, Siegmund KD, Weisenberger DJ, et al. Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol. Biomarkers Prev. 17(11), 3208-3215 (2008).
12. Groff RJ, Nash R, Ahnen DJ: Significance of serrated polyps of the colon. Curr. Gastroenterol. Rep. 10(5), 490-498 (2008).
13. Kambara T, Simms LA, Whitehall VL, et al. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 53(8), 1137-1144 (2004). (Pubitemid 38961968)
14. O'Brien MJ, Yang S, Mack C, et al. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points. Am. J. Surg. Pathol. 30(12), 1491-1501 (2006). (Pubitemid 44808785)
15. Sugumar A, Sinicrope FA: Serrated polyps of the colon. F1000 Med. Reports 2, 89 (2010).
16. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J. Clin. Oncol. 20(4), 1043-1048 (2002). (Pubitemid 34141849)
17. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58(22), 5248-5257 (1998). (Pubitemid 28521189)
18. Gafa R, Maestri I, Matteuzzi M, et al. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer 89(10), 2025-2037 (2000).
19. Halling KC, French AJ, McDonnell SK, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J. Natl Cancer Inst. 91(15), 1295-1303 (1999). (Pubitemid 29387571)
20. Thibodeau SN, French AJ, Cunningham JM, et al. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res. 58(8), 1713-1718 (1998). (Pubitemid 28215098)
21. Sinicrope FA, Rego RL, Halling KC, et al. Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin. Cancer Res. 12(9), 2738-2744 (2006).
22. Lanza G, Gafa R, Maestri I, Santini A, Matteuzzi M, Cavazzini L: Immunohistochemical pattern of MLH1/MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod. Pathol. 15(7), 741-749 (2002). (Pubitemid 34787310)
23. Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J. Med. Genet. 41(9), 664-668 (2004). (Pubitemid 39208606)
24. Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA 296(12), 1479-1487 (2006). (Pubitemid 44465512)
25. Balmana J, Stockwell DH, Steyerberg EW, et al. Prediction of MLH1 and MSH2 mutations in Lynch syndrome. JAMA 296(12), 1469-1478 (2006). (Pubitemid 44465511)
26. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N. Engl. J. Med. 354(26), 2751-2763 (2006). (Pubitemid 43974193)
27. Sinicrope F, Foster NR, Sargent DJ, Thibodeau SN, Smyrk TC, O?Connell MJ: Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. Cancer 116(7), 1691-1698 (2010).
28. Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med. 342(2), 69-77 (2000). (Pubitemid 30036597)
29. Haddad R, Ogilvie RT, Croitoru M, et al. Microsatellite instability as a prognostic factor in resected colorectal cancer liver metastases. Ann. Surg. Oncol. 11(11), 977-982 (2004). (Pubitemid 40486663)
30. Malesci A, Laghi-L, Bianchi P, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin. Cancer Res. 13(13), 3831-3839 (2007). (Pubitemid 47037588)
31. Sinicrope FA, Rego RL, Halling KC, et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 131(3), 729-737 (2006). (Pubitemid 44307064)
32. Lanza G, Gafa R, Santini A, Maestri I, Guerzoni L, Cavazzini L: Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J. Clin. Oncol. 24(15), 2359-2367 (2006). (Pubitemid 46630668)
33. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 349(3), 247-257 (2003). (Pubitemid 36859476)
34. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23(3), 609-618 (2005). (Pubitemid 46224239)
35. Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J. Clin. Oncol. 25(7), 767-772 (2007). (Pubitemid 350002875)
36. Lamberti C, Lundin S, Bogdanow M, et al. Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer. Intl J. Colorectal Dis. 22(2), 145-152 (2007). (Pubitemid 44964017)
37. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 28(20), 3219-3226 (2010).
38. Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, Kerr DJ: Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370(9604), 2020-2029 (2007).
39. Kerr D, Gray R, Quirke P et al.; Quasar Colon Teams: A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J. Clin. Oncol. 27(Suppl. 15), (Abstract 4000) (2009).
40. Tejpar S, Bosman F, Delorenzi M, et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). J. Clin. Oncol. 27(Suppl. 15), (Abstract 4001) (2009).
41. Dolcetti R, Guidoboni M, Viel A, Boiocchi M: Correspondence re: Samowitz etal.: Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol. Biomark. Prev. 10, 917-923 (2001).
42. Cancer Epidemiol. Biomarkers Prev. 11(5), 499; author reply 499-500 (2002).
43. Sinicrope FA, Rego RL, Garrity-Park MM, et al. Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. Intl J. Cancer 120(6), 1232-1238 (2007).
44. Drescher KM, Sharma P, Lynch HT: Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch syndrome patients. Clin. Develop. Immunol. 170432 (2010).
45. Benatti P, Gafa R, Barana D, et al. Microsatellite instability and colorectal cancer prognosis. Clin. Cancer Res. 11(23), 8332-8340 (2005). (Pubitemid 41746945)
46. Jover R, Zapater P, Castells A, et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur. J. Cancer 45(3), 365-373 (2009).
47. Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology 126(2), 394-401 (2004). (Pubitemid 38182296)
48. Jover R, Zapater P, Castells A, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 55(6), 848-855 (2006). (Pubitemid 43764557)
49. Hemminki A, Mecklin JP, Jarvinen H, Aaltonen LA, Joensuu H: Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy- Gastroenterology 119(4), 921-928 (2000).
50. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, Iacopetta B: Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355(9217), 1745-1750 (2000). (Pubitemid 30265078)
51. Des Guetz G, Schischmanoff O, Nicolas P, Perret GY, Morere JF, Uzzan B: Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur. J. Cancer 45(10), 1890-1896 (2009).
52. Carethers JM, Chauhan DP, Fink D, et al. Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117(1), 123-131 (1999). (Pubitemid 29297628)
53. Arnold CN, Goel A, Boland CR: Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Intl J. Cancer 106(1), 66-73 (2003). (Pubitemid 36750389)
54. Kat A, Thilly WG, Fang WH, Longley MJ, Li GM, Modrich P: An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc. Natl Acad. Sci. USA 90(14), 6424-6428 (1993). (Pubitemid 23207225)
55. Branch P, Aquilina G, Bignami M, Karran P: Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362(6421), 652-654 (1993). (Pubitemid 23109278)
56. Vilar E, Scaltriti M, Balmana J, et al. Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. Br. J. Cancer 99(10), 1607-1612 (2008).
57. Magrini R, Bhonde MR, Hanski ML, et al. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Intl J. Cancer 101(1), 23-31 (2002). (Pubitemid 34832993)
58. Rodriguez R, Hansen LT, Phear G, et al. Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11. Clin. Cancer Res. 14(17), 5476-5483 (2008).
59. Fink D, Nebel S, Aebi S, et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56(21), 4881-4886 (1996). (Pubitemid 26374423)
60. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J. Clin. Oncol. 27(11), 1814-1821 (2009).
61. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E: Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther. 1(3), 227-235 (2002).
62. Kim ST, Lee J, Park SH, et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother. Pharmacol. 66(4), 659-667 (2010).
63. des Guetz G, Mariani P, Cucherousset J, et al. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res. 27(4C), 2715-2719 (2007). (Pubitemid 47227987)
64. Chua W, Goldstein D, Lee CK, et al. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br. J. Cancer 101(6), 998-1004 (2009).
65. Zaanan A, Cuilliere-Dartigues P, Guilloux A, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann. Oncol. 21(4), 772-780 (2010).
66. Sanchez EV Chow A, Raskin L, Iniesta MD, Mukherjee B, Gruber SB: Preclinical testing of the PARP inhibitor ABT-888 in microsatellite instable colorectal cancer. J. Clin. Oncol. 27(Suppl. 15), (Abstract 11028) (2009).
67. Atlanta: American Cancer Society: Cancer facts & figures 2010 www5.cancer.org/downloads/STT/Cancer- Facts-and-Figures-2010.pdf